Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term ...

Irvine, California-based Inari, which was founded in 2013, is a maker of devices and systems that treat patients suffering from a variety of blood clot conditions including pulmonary embolism, deep ...

Inari is poised to enhance Stryker's footprint ... These solutions are designed to treat peripheral vascular conditions such as pulmonary embolism and deep vein thrombosis. They claim to remove ...

Stryker acquires Inari Medical for $80/share ... for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Also Read: Morgan Stanley Maintains Positive MedTech Outlook ...

Inari Medical Background Information (This ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep ...

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...

Irvine, California-based Inari, which was founded in 2013, is a maker of devices and systems that treat patients suffering from a variety of blood clot conditions including pulmonary embolism, deep ...

Inari’s product portfolio is complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and ...

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...